Young T. Kwon, PhD has been a director since October 2021 and chairs both the Compensation Committee and the Audit Committee. He served as Chief Executive Officer of Alchemab Therapeutics from April 2022 to September 2024 and held senior leadership roles at Momenta Pharmaceuticals from 2011 to 2021, including Chief Financial and Business Officer, where he led the company's $6.5 billion sale to Johnson & Johnson. He earlier worked in business development at Biogen and as a venture investor at Advanced Technology Ventures.